ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 576-600 of 1,000 matching filings.

Per page
25
Current page
24
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
04 Jan 2022
Reporting date
04 Jan 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL

Filing date
29 Dec 2021
Reporting date
29 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG

Filing date
21 Dec 2021
Reporting date
21 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA

Filing date
20 Dec 2021
Reporting date
20 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE

Filing date
20 Dec 2021
Reporting date
20 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Dec 2021
Reporting date
15 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

EVUSHELD US FDA EUA

Filing date
09 Dec 2021
Reporting date
09 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN

Filing date
07 Dec 2021
Reporting date
07 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Dec 2021
Reporting date
01 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Dec 2021
Reporting date
01 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA

Filing date
30 Nov 2021
Reporting date
30 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Nov 2021
Reporting date
15 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZN: YEAR TO DATE AND Q3 2021 RESULTS

Filing date
12 Nov 2021
Reporting date
12 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Nov 2021
Reporting date
01 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR

Filing date
01 Nov 2021
Reporting date
01 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER

Filing date
25 Oct 2021
Reporting date
25 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER

Filing date
18 Oct 2021
Reporting date
18 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER

Filing date
15 Oct 2021
Reporting date
15 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS

Filing date
12 Oct 2021
Reporting date
12 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU GRANTED BTD FOR BREAST CANCER

Filing date
04 Oct 2021
Reporting date
04 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Oct 2021
Reporting date
01 Oct 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
30 Sep 2021
Reporting date
30 Sep 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES

Filing date
29 Sep 2021
Reporting date
29 Sep 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SAPHNELO APPROVED IN JAPAN FOR SLE

Filing date
28 Sep 2021
Reporting date
28 Sep 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT

Filing date
24 Sep 2021
Reporting date
24 Sep 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .